Mobile-Directly Observed Therapy on Adherence to Hydroxyurea

PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

April 28, 2017

Primary Completion Date

January 28, 2018

Study Completion Date

May 18, 2018

Conditions
Sickle Cell Anaemia
Interventions
DRUG

Hydroxyurea

Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring

DEVICE

Mobile Directly Observed Therapy

Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.

Trial Locations (1)

11101

Muhimbili University of Health and Allied Sciences, Dar es Salaam

All Listed Sponsors
collaborator

University of Pittsburgh

OTHER

collaborator

Muhimbili National Hospital

UNKNOWN

lead

Muhimbili University of Health and Allied Sciences

OTHER

NCT02844673 - Mobile-Directly Observed Therapy on Adherence to Hydroxyurea | Biotech Hunter | Biotech Hunter